Sensydia, a clinical-stage medical technology company advancing non-invasive cardiac assessment, has announced an oversubscribed initial closing of more than US$6 million in its latest financing. The round was led by Colle Capital Partners with substantial support from Orlando Health Ventures. Proceeds will carry the company’s Cardiac Performance System through its ACOUSTIC-1 study to FDA authorization while supporting commercial launch preparation.
Funding Purpose and Clinical Focus
The new capital will support the Cardiac Performance System, a platform designed to give clinicians pulmonary pressure assessments in almost any setting without the need for invasive catheterization. CPS acquires acoustic and electrical signals and analyzes them using artificial intelligence algorithms. The system is intended to help identify congestion and guide diagnosis and treatment in heart failure and pulmonary hypertension.
Regulatory Momentum
In July 2026, a new Category III CPT code, 1036T, took effect for non-invasive hemodynamic assessment. The code covers three key elements: passively acquired acoustic and electrical signals, augmentative algorithmic analysis, and physician review, interpretation, and integration into clinical care. Sensydia notes that CPS is built on the same clinical approach described by this code.
Executive and Investor Perspectives
Bill Hawkins, retired Chairman and CEO of Medtronic and an advisor to Sensydia, said the most important medical technology companies create categories rather than compete in them. He added that Sensydia has the makings of such a company by bringing pressure information to the point of care and building a foundation to scale it. Anthony Arnold, CEO of Sensydia, said cardiologists treating heart failure need the right metric, in the right place, at the right time.
Arnold emphasized that the company built CPS to give clinicians objective pressure information in the office, where therapy decisions are made. Victoria Grace, Founding Partner of Colle Capital Partners, said Sensydia built CPS on catheterization data, the clinical gold standard, at a scale few companies attempt. She added that this discipline, together with a CPT code already in place, gives the firm confidence in the team.
Commercial and Market Context
The financing arrives as healthcare providers seek alternatives to invasive procedures for measuring cardiac pressures. CPS is designed to support clinical decision making in outpatient settings where heart failure therapy is commonly managed. Sensydia expects the new CPT code to help integrate non-invasive hemodynamic assessment into routine care more efficiently and predictably.
Investor Profiles
Colle Capital Partners is a global, opportunistic, early stage technology venture fund that invests in AI native businesses, deep technology, and infrastructure. Orlando Health Ventures advances healthcare innovation through strategic investments in companies transforming the healthcare industry. Both investors bring strategic and clinical resources that may support Sensydia’s path to market.
Company Background and Regulatory History
Sensydia is developing the Cardiac Performance System as a non-invasive platform for rapid, safe, and accurate assessments of hemodynamic function in the office or clinic. The technology has received FDA Breakthrough Device designation, and the company obtained FDA 510(k) clearance in 2018 for an algorithm that measures ejection fraction non-invasively. CPS is currently for investigational use only and is not yet authorized by the FDA.
The initial closing positions Sensydia to complete its ACOUSTIC-1 study and move toward FDA authorization for its cardiac assessment platform. With new backing from Colle Capital Partners and Orlando Health Ventures, the company is preparing for a commercial launch built around a recently established CPT code. The financing reflects growing investor confidence in non-invasive hemodynamic monitoring for heart failure and pulmonary hypertension.